Interleukin-5 in the Pathophysiology of Severe Asthma

Cost-effectiveness and comparative effectiveness of biologic therapy for asthma

(2019) William C. Anderson et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials: Bridging Clinical and Patient Perspectives

(2019) Salman Siddiqui et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Treatable traits in chronic rhinosinusitis with nasal polyps

(2019) Enrico Heffler et al.   Current Opinion in Allergy and Clinical Immunology

Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases

(2019) Hemanth Kumar Kandikattu et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The Cytokines of Asthma

(2019) Bart N. Lambrecht et al.   IMMUNITY

Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma

(2019) I Dávila González et al.   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

Inflammation and Endotyping in Chronic Rhinosinusitis—A Paradigm Shift

(2019) Sinead Ahern et al.   Medicina-Lithuania

Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose

(2019) Corrado Pelaia et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

(2018) Bradley E. Chipps et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy

(2018) Corrado Pelaia et al.   Drug Design Development and Therapy

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma

(2018) Corrado Pelaia et al.   Biomed Research International

Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps

(2018) Enrico Heffler et al.   Expert Review of Clinical Immunology

Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma

(2018) Anurag Bhalla et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study

(2018) Corrado Pelaia et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Role of Biologics in Asthma

(2018) Mary Clare McGregor et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma

(2018) Diego Bagnasco et al.   Biomed Research International

Eosinophils Target Therapy for Severe Asthma: Critical Points

(2018) L. Brussino et al.   Biomed Research International

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

(2018) William W Busse et al.   Lancet Respiratory Medicine

The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials

(2018) Diego Bagnasco et al.   World Allergy Organization Journal

Asthma and corticosteroids: time for a more precise approach to treatment

(2017) Eleanor M. Dunican et al.   EUROPEAN RESPIRATORY JOURNAL

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils

(2017) Guy Brusselle et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

(2017) Corrado Pelaia et al.   Drug Design Development and Therapy

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Gary T Ferguson et al.   Lancet Respiratory Medicine

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

(2017) Gilda Varricchi et al.   Frontiers in Immunology

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels

(2016) Leif Bjermer et al.   CHEST

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders

(2016) Gilda Varricchi et al.   Current Opinion in Allergy and Clinical Immunology

The role of interleukin 5 in asthma

(2016) Gilda Varricchi et al.   Expert Review of Clinical Immunology

Mepolizumab in the treatment of severe eosinophilic asthma

(2016) Valentina Fainardi et al.   Immunotherapy

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

(2016) Steven G. Smith et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience

(2016) Gilda Varricchi et al.   Therapeutic Advances in Respiratory Disease

Role of biologics in severe eosinophilic asthma – focus on reslizumab

(2016) Girolamo Pelaia et al.   Therapeutics and Clinical Risk Management

Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB–induced Bcl-x L for inhibition of apoptosis

(2015) Christian Schwartz et al.   BLOOD

Mepolizumab-based therapy in asthma

(2015) Garry M. Walsh   Current Opinion in Allergy and Clinical Immunology

Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma

(2015) Girolamo Pelaia et al.   MEDIATORS OF INFLAMMATION

The immunology of asthma

(2015) Bart N Lambrecht et al.   NATURE IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Asthma

(2015) Stephen T. Holgate et al.   Nature Reviews Disease Primers

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)

(2014) F. Schleich et al.   RESPIRATORY MEDICINE

Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma

(2013) Guy G Brusselle et al.   NATURE MEDICINE

Targeting eosinophils in allergy, inflammation and beyond

(2013) Patricia C. Fulkerson et al.   NATURE REVIEWS DRUG DISCOVERY

Effect of Sch 55700, a Humanized Monoclonal Antibody to Human Interleukin-5, on Eosinophilic Responses and Bronchial Hyperreactivity

(2012) Robert Egan et al.   ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH

The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling

(2012) Sophie E. Broughton et al.   IMMUNOLOGICAL REVIEWS

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Reslizumab for Poorly Controlled, Eosinophilic Asthma

(2011) Mario Castro et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

(2011) N. A. Molfino et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

(2011) Aasia Ghazi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Ultrastructural evidence for human mast cell-eosinophil interactions in vitro

(2010) Yael Minai-Fleminger et al.   CELL AND TISSUE RESEARCH

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

What targeting eosinophils has taught us about their role in diseases

(2010) Bruce S. Bochner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma

(2009) Prescott G. Woodruff et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

IL-5- and eosinophil-mediated inflammation: from discovery to therapy

(2009) T. Kouro et al.   INTERNATIONAL IMMUNOLOGY

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eosinophils: Biological Properties and Role in Health and Disease

(2008) SIMON P. HOGAN et al.   CLINICAL AND EXPERIMENTAL ALLERGY

IL-5 and eosinophilia

(2008) Kiyoshi Takatsu et al.   CURRENT OPINION IN IMMUNOLOGY

Structure-Based Rationale for Interleukin 5 Receptor Antagonism

(2008) Tetsuya Ishino et al.   CURRENT PHARMACEUTICAL DESIGN